



ASX ANNOUNCEMENT

27 November 2013

UPDATED STATEMENT OF FINANCIAL POSITION

The Board of Cynata Therapeutics Limited (ASX: CYP) annex an updated Statement of Financial Position as at 30 June 2013 based on the actual amount of funds raised pursuant to the Prospectus of \$5 million.

Dr Ross Macdonald

Managing Director & Chief Executive Officer
+61 412 119 343

About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

**CYNATA THERAPEUTICS LIMITED
CONDENSED STATEMENT OF FINANCIAL
POSITION**

	Eco Quest 30 June 13	Unaudited Consolidated Pro Forma
Current Assets		
Cash and cash equivalents	1,116,587	6,156,055
Trade and other receivables	32,261	35,677
Total Current Assets	1,149,848	6,191,732
Non-Current Assets		
Plant and equipment	-	892
Investment in associates	642,695	-
Investment in subsidiary	-	-
Technology intangibles	-	4,805,565
Total Non-Current Assets	642,695	4,806,457
Total Assets	1,792,543	10,998,189
Current Liabilities		
Trade and other payables	13,988	-
Provisions	135,712	7,592
Total Current Liabilities	149,700	7,592
Total Liabilities	149,700	7,592
Net Assets	1,642,843	10,990,597
Equity		
Issued capital	12,338,120	22,168,822
Option reserve	1,544,052	2,626,192
Accumulated (profit)/losses	(12,239,329)	(13,804,417)
Net Equity	1,642,843	10,990,597